UNC Health Medication Formulary
Add Formweb to your mobile device
System Formulary Update
Sutimlimab-jome (Enjaymo) 1100 mg/22 mL SDV
December 9, 2025
Situation
Sutimlimab-jome (Enjaymo) was approved for addition to the UNC Health system formulary at the October 2025 System Pharmacy and Therapeutics Committee meeting.
Background
The following medication was reviewed: Sutimlimab-jome (Enjaymo)
Assessment/Recommendation
Change effective: Tuesday, December 16, 2025
- System P&T voted to include the following product on the UNC Health Medication Formulary: Sutimlimab-jome (Enjaymo) with the following restrictions:
- Outpatient: Restricted to patients w/cold agglutinin disease who have failed ≥ 1 line of prior systemic therapy AND benefits investigation must be completed prior to use
- Inpatient: Restricted to patients who meet 1 of the following criteria:
- New start therapy for patients w/cold agglutinin disease who have failed ≥ 1 line of prior systemic therapy AND orders must be approved by the Coagulation Consult Service OR Hematology/Oncology Service
- Continuation of home/previously established therapy & administration cannot be deferred to resume in outpatient setting. Orders must be approved by the Coagulation Consult Service OR Hematology/Oncology Service